Characteristic | N (%) | Characteristic | N (%) |
---|---|---|---|
Age (years) | ER/PR status | 81 (100) | |
Mean (SD) | 65.6 (10.58) | ER-positive | 80 (98.77) |
Median (range) | 66 (36–82) | ER-negative | 1 (1.23) |
PR-positive | 51 (62.96) | ||
Stage at diagnosis | PR-negative | 4 (4.94) | |
Stage 1 | 36 (44.44) | PR-unknown | 26 (32.10) |
Stage 2 | 45 (55.56) | ||
HER2 status | |||
HER2-positive | – | ||
Histology | HER2-negative | 81 (100) | |
Ductal invasive | 36 (44.44) | ||
Lobular invasive | 36 (44.44) | Ki67 status (%) | |
Others | 9 (11.12) | Mean (SD) | 26.76 (20.44) |
Median (range) | 25 (3–90) | ||
Tumor size | Ki67 < 15% | 22 (27.16) | |
≤ 20 mm | 34 (41.98) | Ki67 ≥ 15% | 29 (35.80) |
20–30 mm | 37 (45.68) | Ki67 unknown | 30 (37.04) |
> 30 mm | 9 (11.11) | ||
Unknown | 1 (1.23) | uPA (ng/mg of protein) | |
Mean (SD) | 4.37 (3.9) | ||
Tumor grade | Median (range) | 3 (0.1–18.7) | |
Grade 1 | 11 (13.58) | uPA ≤ 3 | 41 (50.62) |
Grade 2 | 67 (82.72) | uPA > 3 | 40 (49.38) |
Grade 3 | 3 (3.70) | ||
PAI-1 (ng/mg of protein) | |||
Nodal status | Mean (SD) | 21.47 (18.89) | |
Node-negative | 75 (92.59) | Median (range) | 16 (0–140) |
Node-positive | – | PAI-1 ≤ 14 | 32 (39.51) |
Unknowna | 5 (6.17) | PAI-1 > 14 | 49 (60.49) |
uPA and PAI-1 combinations | |||
uPA ≤ 3 and PAI-1 ≤ 14 | 30 (37.04) | ||
uPA ≤ 3 and PAI-1 > 14 | 11 (13.58) | ||
uPA > 3 and PAI-1 ≤ 14 | 2 (2.47) | ||
uPA > 3 and PAI-1 > 14 | 38 (46.91) |